New cell therapy aims to stop blood cancer relapse in tough-to-treat patients
NCT ID NCT07566585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new cell therapy called BSB-2002 in adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to at least two prior treatments. The main goals are to check safety and see if it can prevent the cancer from coming back. About 19 participants will receive the therapy at different doses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University at St Louis
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill tackle Tough-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can a triple-drug combination tame AML without intensive chemo?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia
- New drug cocktail aims to boost remission in tough AML cases